NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Wall S
Post# of 148292
(Total Views: 325)
Posted On: 11/12/2019 3:45:21 PM
NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Wall Street Reporter will be hosting the “NEXT SUPER STOCK - Live!” livestream online-only investor conference on Thursday, November 14, 2019 from 12:30PM-1:30PM EST. Registration is free. Click here to join: https://www.wallstreetreporter.com/next-super...onference/
Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have major near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead.
CytoDyn, Inc. (CYDY)
CytoDyn, Inc. CEO Nader Pourhassan, Ph.D, will be making his second NEXT SUPER STOCK conference appearance, which is highly anticipated by the thousands of investors worldwide who follow CYDY.
Dr. Pourhassan will be discussing the company’s latest progress for its leronlimab monoclonal antibody drug platform, and its pipeline targeting HIV, multiple cancer indications, and immune-mediated illnesses, such as GvHD and NASH, which have blockbuster revenue potential.
CYDY’s lead drug candidate, leronlimab (PRO 140) for treating HIV, is expected to receive FDA approval in mid 2020. Investors attention is also on the possibility of CytoDyn's HIV monotherapy potential receiving FDA approval as label expansion, potentially in 2021. CytoDyn's monotherapy is a potential "game changer" in HIV treatment, requiring only once-weekly dose which could be self-administered.
A question & answer session will follow the presentation, and investors are invited to submit questions in advance, or during the live session.
Click here to register for the livestream conference presentatons:
https://www.wallstreetreporter.com/next-super...onference/
Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have major near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead.
CytoDyn, Inc. (CYDY)
CytoDyn, Inc. CEO Nader Pourhassan, Ph.D, will be making his second NEXT SUPER STOCK conference appearance, which is highly anticipated by the thousands of investors worldwide who follow CYDY.
Dr. Pourhassan will be discussing the company’s latest progress for its leronlimab monoclonal antibody drug platform, and its pipeline targeting HIV, multiple cancer indications, and immune-mediated illnesses, such as GvHD and NASH, which have blockbuster revenue potential.
CYDY’s lead drug candidate, leronlimab (PRO 140) for treating HIV, is expected to receive FDA approval in mid 2020. Investors attention is also on the possibility of CytoDyn's HIV monotherapy potential receiving FDA approval as label expansion, potentially in 2021. CytoDyn's monotherapy is a potential "game changer" in HIV treatment, requiring only once-weekly dose which could be self-administered.
A question & answer session will follow the presentation, and investors are invited to submit questions in advance, or during the live session.
Click here to register for the livestream conference presentatons:
https://www.wallstreetreporter.com/next-super...onference/
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼